We during the outbreak.
Release time:
2020-07-15
Spring Festival 2020, the sudden outbreak of new coronavirus pneumonia disrupted everyone's daily life and work. The Central Committee of the Communist Party of China has decisively made various decisions and arrangements for the prevention and control of the epidemic, and the whole country has set off a war of epidemic prevention and control without gunpowder smoke.
The outbreak of novel coronavirus pneumonia has caused great concern among group leaders and made corresponding predictions. According to the relevant notice of the group and the spirit of the new coronavirus prevention and control meeting of the pharmaceutical company on January 27, Jianfeng Pharmaceutical Factory will allow employees to clock in on their mobile phone DingTalk every day starting from January 28 to fully understand each employee's movements during the Spring Festival, living history, epidemiological history, contact personnel and other relevant information. Track and arrange the health of each employee, learn the Operation Manual for Resuming Trainees to prepare for the resumption of work.
On February 10, the peak pharmaceutical factory resumed work. As the application for resumption of work requires the number of employees, although the employees in the factory are basically local, the pharmaceutical factory can only arrange the return time of the employees according to their posts. Just two days before returning to work, everyone was quite panicked and took precautions to minimize the risk of infection. Masks were also worn on the way to and from work and in the office, keeping a distance of more than one meter between people, and they just nodded when they met. There was no usual heat at all.
Due to limited logistics and transportation conditions during the outbreak, many raw materials could not be shipped in time, and production was affected. According to the inventory of raw and auxiliary materials and the resumption of personnel, the factory first arranged the powder injection workshop to produce penciclovir for injection on February 13. After the comprehensive preparation workshop completed the packaging of finished amlodipine aspartate tablets, it also started production of amlodipine aspartate tablets on February 14. With the gradual improvement of the epidemic situation, the resumption of work personnel is not limited, logistics and transportation returned to normal, a variety of required raw materials in place, the fear of employees also slowly tend to stabilize, all production lines also began to operate. The raw material workshop was started to produce amlodipine aspartate raw materials, and the preparation workshop was started to produce ofloxacin eye drops. At present, with the joint efforts of everyone, in addition to one Hubei employee, all other personnel to the post, the pharmaceutical plant has been fully safe and orderly to promote the resumption of production, production capacity has been restored to about 90%.
This epidemic deserves deep reflection, in the days when the epidemic affects the inability to work, it actually tests the personal lifestyle. In the past days, work dominated, personal time was very small, and it was easy to enrich. Most people's lives were mainly material and spiritual. Suddenly there is a lot of leisure time, but it becomes confused, anxious, and life has no direction. Fortunately, after the epidemic, everyone has grown up in life. Although the streets on the road are deserted, the WeChat circle of friends is still in full swing. Friends basked in cold skins yesterday, made cakes today, and will share other surprises tomorrow. Our fast-paced life is disrupted, but the slow-down life is not the same wonderful.
During the active resumption of work, the test is the country and the business, and the epidemic is challenging all walks of life. Although everyone always said at home that they wanted to go to work, when it was time to return to work, everyone was uneasy. Only when the enterprise reasonably formulates and strictly implements the resumption plan and measures, can each employee feel at ease and resume work without worries, thus improving work efficiency and restoring production capacity to the maximum. (Zhang Zhijian)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page